India Proposes Easing Price Controls For Some Makers Of Key Drugs
This article was originally published in PharmAsia News
India's Cabinet ministers have proposed a certification process to give makers of key drugs an added advantage in setting prices. The proposal sent to the Law Ministry would offer a "gold standard" certificate to companies that meet certain conditions, including having at least 200 scientists on staff. Another requirement would be to have at least one manufacturing facility approved by two foreign regulators and to spend at least 5 percent of turnover on research and development. The certificate would allow them to claim a 200 percent maximum allowable post-manufacturing expense, compared with 150 percent for unqualified firms. The change would affect prices on 354 lifesaving drugs the government wants to bring under price controls. (Click here for more
You may also be interested in...
In a bold move to expand into cancer treatment markets, Siemens Healthineers has agreed to a $16.4bn all-cash deal to acquire radiation therapy leader Varian.
Concern and skepticism about Russia's rapid vaccine roll-out. Meanwhile Japan is latest to reach reaches deal with Pfizer/BioNTech.
Sun’s Q1 earnings were dented by provisions related to the generic pricing investigation settlement with the US Department of Justice of arm Taro, and the impact of pandemic-related lockdowns. Some clinic-administered products bore the brunt of lock-downs in parts of the US, though market share was unaffected.